A platform for modifying proteins to enhance immune response against cancer
Official title: Chimeric Ligands for Induced Proximity (CLIP) platform for targeted proteome editing and upregulation of antigen presentation
Funded at Ubiquitx, INC. · NIH-11006699 · Data updated 2026-11-12
This study is exploring a new way to help the immune system better spot and attack cancer cells, especially in patients with Acute Myeloid Leukemia (AML), by using advanced technology to change certain proteins on the surface of these cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ubiquitx, INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 10, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $299,921 |
| NIH project number | 1R41AI186686-01 |
| Project ID | NIH-11006699 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia or other cancers where immune evasion is a concern.
✕Less likely to help
Patients with cancers that do not involve MHC-I downregulation or those not responding to immune therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic platform that modifies specific proteins to improve how the immune system recognizes and targets diseased cells, particularly in cancers like Acute Myeloid Leukemia (AML). By utilizing advanced techniques in artificial intelligence and protein engineering, the platform aims to enhance the presentation of antigens on the surface of cells, making them more visible to T cells, which are crucial for immune defense. The approach involves precise editing of proteins to either add or remove modifications that influence their visibility to the immune system, potentially leading to better patient outcomes in cancer treatment.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of immune-based therapies for patients with certain cancers.
How similar studies have gone: Other research has shown promise in enhancing immune responses through similar protein modification techniques, indicating potential for success in this novel approach.
Where this research is happening
-
Ubiquitx, INC.
New York, United States Active
Researchers
- Principal investigator: Camargo, Luiz Miguel Quinn — Ubiquitx, INC.
- Study coordinator: Camargo, Luiz Miguel Quinn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.